Mankind Pharma is one of the Indian leading pharmaceutical companies and changes the pharma industry. They deliver world-class drugs at economical pricing.
Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 17,000 and are racing towards $1 Billion. Humanity aspires to help the population live a healthy life by creating, commercializing, and providing inexpensive and accessible medications that address urgent medical needs. We are quite proud of the success of our Pharma, OTC, and FMCG brands such as Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel, and many others. Our activities are in 34 abroad destinations spanning Asia, Africa, South-East Asia, Gulf countries, and CIS countries.
Company Financial Performance
Capital International paid $200 million for an 11% stake in Mankind from ChrysCapital in 2015. ChrysCapital purchased a 10% stake in the company again in April 2018 for approximately $350 million.
In April this year, Mankind Pharma announced the creation of Mankind Agritech Pvt Limited to expand into the agritech industry and the business claimed it will invest ₹200 crore in the next two to three years.
Mankind Pharma’s Stock Evaluation
Zacks’ internal research suggests that MannKind Corporation is now classified as a Zacks Rank 3 and we are anticipating an inline return from the MNKD shares relative to the market in the next several months. In addition, MannKind Corporation has a VGM Score of D (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). Valuation measures suggest that MannKind Company may be overpriced. Its Value Score of D implies it would be a lousy selection for value investors.
MNKD’s financial health and growth prospects show that it has the potential to underperform the market. It currently has a Growth Score of C. With a Momentum Score of D, recent price changes and earnings estimate revisions indicate that this is not a good stock for momentum investors.
MNKD is a pharmaceutical firm that has had its fair share of hurdles in recent years. The company’s financial success has been erratic, and it confronts strong competition in the diabetic industry. However, there are some positive signs in the company’s financials, and there is growing demand for inhaled insulin products. Furthermore, MNKD has several promising products in its pipeline and has formed partnerships to accelerate growth. Finally, whether MNKD is a good stock to buy is determined by individual investors’ risk tolerance and investment objectives. It is vital to undertake complete research and talk with a registered financial advisor before making any investing decisions.
Please continue to read new articles here about merchandise assessed by Waytrade.